Clinical Trials Logo

Renal Transplant Rejection clinical trials

View clinical trials related to Renal Transplant Rejection.

Filter by:

NCT ID: NCT01953120 Completed - Clinical trials for Renal Transplant Rejection

Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

Start date: October 2013
Phase: Phase 4
Study type: Interventional

This research evaluates the effectiveness of a new drug called belatacept (Nulojix) for the prevention of acute rejection and preservation of kidney function in transplant patients. Belatacept was approved in 2011 by the United States Food and Drug Administration (FDA) and is being marketed as Nulojix. The pharmaceutical company sponsoring this study is Bristol-Myers Squibb. Belatacept is a prescription medicine used in adults to prevent transplant rejection in people who have received a kidney transplant. Transplant rejection happens when the body's immune system senses that the new transplanted kidney is different or foreign, and attacks it. Belatacept is used with corticosteroids and certain other medicines to help prevent rejection of your new kidney. The purpose of the research is to understand whether the new drug, belatacept, is better than other anti-rejection drugs, such as cyclosporine and tacrolimus that are typically used in the treatment against kidney rejection in transplant patients.

NCT ID: NCT01239472 Completed - Immunosuppression Clinical Trials

Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant

Start date: January 2011
Phase: Phase 4
Study type: Interventional

Currently, acute kidney injury is diagnosed by increased serum creatinine. However, creatinine is not a reliable marker for acute changes in renal function. The biology of the renal graft is influenced by chemokines from reperfusion (just after the kidney transplant) and throughout its course, when acute and chronic inflammatory changes occurs. Moreover, the evaluation of changes in urinary cytokines reflects kidney interstitial patterns, and can predict renal function, acute rejection episodes and their response to treatment. Today there are several studies comparing the relative immunosuppression of renal function, but few noticed its relationship with cytokines and chemokines. Thus, we proposed studying the inflammatory consequences of early calcineurin inhibitors (ICN) withdrawing in transplant patients by urine analysis. Kidney biopsy was done before ICN withdrawn and replaced by everolimus (3 months after transplant), and 1 year after transplant.

NCT ID: NCT00866879 Completed - Clinical trials for Renal Transplant Rejection

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

Start date: June 2007
Phase: Phase 4
Study type: Interventional

This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant. The primary purpose of this research study is to evaluate whether the use of mycophenolate mofetil(MMF)/Cellcept® and tacrolimus(TAC)/Prograf® (Group 1) or mycophenolate mofetil(MMF)/Cellcept® and sirolimus/Rapamune® (Group 2) impacts the incidence of acute cellular rejection in post kidney transplant patients. This study will examine whether switching from tacrolimus to sirolimus will better preserve long-term kidney function.

NCT ID: NCT00771745 Completed - Clinical trials for Renal Transplant Rejection

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

Start date: September 2008
Phase: Phase 4
Study type: Interventional

To determine how safe and effective giving Thymoglobulin before transplantation to patients who are going to be receiving kidney transplants.

NCT ID: NCT00695097 Completed - Clinical trials for Renal Transplant Rejection

The Effect of Rituximab on the Development of Anti-Donor Antibodies

Start date: August 2004
Phase: N/A
Study type: Interventional

The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process. Our hypothesis is that with acute rejection there is activation of B cells and the subsequent development of anti-donor antibodies that ultimately lead to graft loss. More effective therapy targeted at B cells may abort the development of anti-HLA antibodies, prevent renal injury and have a favorable effect on long-term graft outcome.

NCT ID: NCT00658073 Completed - Clinical trials for Renal Transplant Rejection

Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts

Start date: March 2008
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantation.